Safety Evaluation Study for Patients With Polycythemia Vera

PHASE1UnknownINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

August 1, 2023

Study Completion Date

March 31, 2024

Conditions
Polycythemia Vera
Interventions
DRUG

PPMX-T003

As an observation and evaluation method, for each dose, in principle, inpatient observation is performed for 1 week from the day before administration, and then safety and pharmacodynamic tests are evaluated by visiting the hospital every 2 weeks.

Trial Locations (3)

573-1191

RECRUITING

Kansai Medical University Hospital, Hirakata

693-8501

RECRUITING

Shimane University Hospital, Izumo

545-8586

RECRUITING

Osaka City University Hospital, Osaka

Sponsors
All Listed Sponsors
lead

Perseus Proteomics Inc.

INDUSTRY

NCT05074550 - Safety Evaluation Study for Patients With Polycythemia Vera | Biotech Hunter | Biotech Hunter